Universe Pharmaceuticals (UPC) Cash & Current Investments (2020 - 2026)

Universe Pharmaceuticals has reported Cash & Current Investments for 7 years, with the latest figure at $29.0 million in Q1 2026.

• Quarterly Cash & Current Investments changed N/A year-over-year to $29.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.0 million (changed N/A YoY) and the FY2025 annual result came in at $33.6 million, down 97.61% from the prior year.
• Cash & Current Investments slipped to $29.0 million in Q1 2026 per UPC's latest filing, from $33.6 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $5.7 billion in Q3 2022 and troughed at $11.4 million in Q1 2024.
• A 5-year average of $1.6 billion and a median of $31.3 million in 2025 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2022 and 2025: Cash & Current Investments jumped 26155.92% in 2022, then tumbled 97.61% in 2025.
• Over 5 years, Cash & Current Investments stood at $5.7 billion in 2022, then slipped by 7.65% to $5.3 billion in 2023, then tumbled by 73.38% to $1.4 billion in 2024, then sank by 97.61% to $33.6 million in 2025, then decreased by 13.52% to $29.0 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $29.0 million, $33.6 million, and $1.4 billion for Q1 2026, Q3 2025, and Q3 2024 respectively.